Cryo-EM reveals how statins trigger calcium leaks in muscle
Knowing the physical mechanism behind statin-induced myopathy gives patients and clinicians an objective basis to manage muscle pain without abandoning cardiovascular prevention.
Cardiologists routinely encounter patients who stop taking statins because their legs ache. Up to 10 percent of people prescribed these cholesterol-lowering drugs report muscle discomfort or weakness, a figure that often gets dismissed as a nocebo effect during clinical consultations. That dismissal is no longer tenable.
A structural biology investigation led by researchers at the University of Geneva resolved the mechanism using cryo-electron microscopy. The team demonstrated that statins directly bind to the ryanodine receptor 1 (RyR1), a large protein channel in skeletal muscle cells that manages the release of intracellular calcium. By lodging in a specific pocket of the receptor, the drug holds the pore open, causing a steady leakage of calcium ions that exhausts the cell and triggers soreness.
The discovery clarifies that statin-associated muscle symptoms reflect measurable biophysics rather than personal frailty. If you take a statin and notice persistent heaviness in your calves, you now have a concrete biological mechanism to discuss with your prescriber. You can review dosing schedules, alternate-day administration, or non-statin lipid therapies using your own symptom logs and baseline blood panels as clear reference points.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.